Welcome to our dedicated page for Sangamo Therapeutics news (Ticker: SGMO), a resource for investors and traders seeking the latest updates and insights on Sangamo Therapeutics stock.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) is a genomic medicine company whose news flow centers on clinical data, regulatory interactions, collaborations and financial updates across its neurology‑focused pipeline. Company announcements emphasize investigational programs in Fabry disease, chronic neuropathic pain and prion disease, along with progress in its zinc finger epigenetic regulation and AAV capsid platforms.
A major theme in recent SGMO news is the development of isaralgagene civaparvovec (ST‑920), a wholly owned investigational gene therapy for adults with Fabry disease. Press releases detail topline and updated results from the registrational Phase 1/2 STAAR study, including positive mean annualized estimated glomerular filtration rate (eGFR) slopes at 52 and 104 weeks, stability of cardiac endpoints, biomarker trends and quality‑of‑life measures. Regulatory milestones, such as FDA agreement to use eGFR slope as an endpoint for an accelerated approval pathway and acceptance of a rolling Biologics License Application (BLA) submission, are also key subjects.
Investors following SGMO news can also track developments in the Phase 1/2 STAND study of ST‑503 for intractable pain due to small fiber neuropathy, including FDA Fast Track Designation, site activation and recruitment updates. Additional releases describe preclinical and regulatory progress for ST‑506 in prion disease, as well as business development activities like the capsid license agreement with Eli Lilly and Company and other collaboration‑related revenues.
Quarterly earnings releases and conference call announcements provide context on Sangamo’s operating expenses, cash position and strategic focus on a neurology‑oriented genomic medicine business. For readers interested in SGMO, this news page aggregates these clinical, regulatory, partnership and financial disclosures in one place, making it easier to follow the company’s reported milestones over time.
Sangamo Therapeutics (SGMO) announced the dosing of the first patient in its Phase 1/2 STEADFAST clinical study for TX200, an innovative CAR-Treg cell therapy aimed at preventing immune-mediated rejection in HLA-A2 mismatched kidney transplants. This represents a significant milestone in genomic medicine, with hopes of reducing the need for lifelong immunosuppressants. The study aims to assess TX200's safety and effectiveness, marking a potential breakthrough in treating patients receiving kidneys from living donors.
Sangamo Therapeutics, a genomic medicine company (NASDAQ: SGMO), will participate in three upcoming investor conferences in March 2022. These include the Cowen 42nd Annual Health Care Conference on March 7 at 12:50 p.m. ET, the Barclays Global Healthcare Conference on March 17 at 9:00 a.m. ET, and the H.C. Wainwright & Co. Gene Editing and Therapy Conference on March 30 at 7:00 a.m. ET. Presentations will be accessible via the company’s website in the Investors and Media section post-event.
For more details about Sangamo's innovative genomic medicines pipeline, visit www.sangamo.com.
Sangamo Therapeutics (SGMO) reported its financial results for Q4 and full year 2021, highlighting advances in genomic medicines across multiple therapeutic areas. The company noted ongoing developments in its gene therapy candidates for Fabry disease and sickle cell disease, alongside its hemophilia A collaboration with Pfizer. However, the firm reported a consolidated net loss of $178.3 million for 2021, compared to a loss of $121.1 million in 2020. Cash, cash equivalents, and marketable securities decreased to $464.7 million by year-end. 2022 operating expense guidance is set between $320 million and $350 million.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced the release date for its fourth quarter and full year 2021 financial results, scheduled for February 24, 2022, after market close. Following this, a conference call will take place at 4:30 p.m. ET to discuss the results and provide business updates. The call can be accessed via telephone or webcast. Details for call-in numbers and a link to the live webcast are available on the company's website. Sangamo focuses on developing genomic medicines for diseases lacking adequate treatment options.
Sangamo Therapeutics has reported updated results from the Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920), a gene therapy for Fabry disease. As of November 9, 2021, the treatment was well tolerated across five patients, with α-Gal A activity significantly elevated in four patients (3-15 times above normal). The fifth patient in the third cohort showed mean normal levels at week 2. Notably, there were no serious adverse events. Sangamo plans to advance to Phase 3 following the completion of the current study, with further results expected throughout 2022.
Sangamo Therapeutics, Inc. announced that Sanofi will transition its rights for
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) has announced that management will present at the H.C. Wainwright BIOCONNECT Virtual Conference on January 10 at 7:00 a.m. Eastern Time. The presentation can be accessed via the company's website in the Investors and Media section and will be available for viewing post-event. Sangamo focuses on genomic medicine using proprietary zinc finger genome engineering technologies to develop new treatments for diseases lacking adequate options.
Pfizer (NYSE: PFE) and Sangamo Therapeutics (NASDAQ: SGMO) have released updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec, a gene therapy for severe hemophilia A. At 104 weeks, patients in the highest dose cohort exhibited a mean factor VIII activity of 25.4% with no annualized bleeding in the first year post-infusion. However, the Phase 3 AFFINE trial has encountered a clinical hold by the FDA following observations of elevated FVIII levels in treated patients. The ongoing studies aim to evaluate long-term efficacy and safety of this investigational therapy.
Sangamo Therapeutics announced positive preliminary data from its Phase 1/2 PRECIZN-1 study of
Sangamo Therapeutics (Nasdaq: SGMO) announced its participation in several upcoming investor conferences. Management will present at the Barclays Gene Editing & Gene Therapy Summit on November 15 at 10:30 a.m. Eastern Time, followed by the Stifel 2021 Virtual Healthcare Conference on the same day at 3:20 p.m. Eastern Time. Additionally, they will participate in the Jefferies London Healthcare Conference on November 16 at 8:40 a.m. Eastern Time. Presentations will be webcasted live and available later on Sangamo's website.